AstraZeneca’s bladder cancer treatment receives FDA approval
3 May 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) to treat metastatic urothelial carcinoma...